Turnstone Biologics(TSBX.US)

Company Encyclopedia
View More
name
Turnstone Biologics
TSBX.US
Turnstone Biologics Corp. operates as a biotechnology company. The company was founded in 2014 and is headquartered in San Diego, California.
1.899 T
TSBX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Peer-Reviewed Study Establishes Consistent Quality and Early Clinical Success of Ossium’s Proprietary Off-the-Shelf Bone Marrow

    A peer-reviewed study published in Cytotherapy highlights the early clinical success of Ossium Health's cryopreserved bone marrow as an off-the-shelf graft for allogeneic hematopoietic cell transplantation. The study demonstrates that Ossium's GMP-manufactured bone marrow can be produced consistently and delivered quickly, overcoming the logistical challenges of fresh grafts. Clinical results from three high-risk AML patients showed rapid engraftment and no adverse events, reinforcing the biological potency of Ossium's approach. This research challenges the assumption that fresh grafts are superior, paving the way for more predictable access to life-saving therapies.

    MorningStar·
    MorningStar·

    U.S. stock movement quick report: Acrivon up nearly 19%, Erasca down over 14%, tech stocks active

    Overview of the US Stock Market In the past hour, the US stock market has shown a clear characteristic of sector rotation, with notable performances from technology and pharmaceutical stocks. In terms of capital flow, investors seem to favor short-term opportunities, particularly looking for breakthroughs in small-cap stocks and thematic stocks. The market pace is fast, volatility has increased, and short-term enthusiasm has significantly risen. The stock with the largest movement in the past hour, Acrivon Therapeutics, leads the market with a 18.98% increase, demonstrating strong capital momentum. The stock's upward trend is steady, attracting a large amount of short-term capital attention, making it the market focus. Strong stocks: 1. Polestar Automotive UK PLC - CW 27: up 17.56%, performing impressively in the automotive sector, with active short-term capital involvement. 2. Next Tech: up 13.01%, benefiting from a favorable market atmosphere due to the active performance of the technology sector. 3. Trident Digital Tech: up 8.41%, with continued heat in the digital technology field driving stock price upward. 4. Aerovironment: up 7.23%, showing clear signs of recovery in the aviation sector, attracting investors' attention. 5. RTX: up 4.79%, with stable performance in the defense technology sector providing support. 6. Ondas: up 3.78%, with innovations in the communication technology field sparking market interest

    Tracking Unusual Activity·
    US
    ACRV
    -9.33%
    Tracking Unusual Activity·
    US
    ACRV
    -9.33%

    After-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates

    Several biotechnology and healthcare companies saw significant after-hours gains on Wednesday due to clinical updates and financial results. ALX Oncology Holdings (ALXO) surged 10.17% after positive Phase 2 trial data. Globus Medical (GMED) climbed 9.34% on strong preliminary sales results, while Acrivon Therapeutics (ACRV) rose 6.44% ahead of upcoming clinical data releases. Other notable gainers included RenovoRx (RNXT), AnaptysBio (ANAB), Omeros Corp (OMER), EUDA Health (EUDA), TherapeuticsMD (TXMD), and Pyxis Oncology (PYXS).

    rttnews·
    US
    GMED
    -0.16%
    US
    ALXO
    +8.87%
    US
    ACRV
    -9.33%
    rttnews·
    US
    GMED
    -0.16%
    US
    ALXO
    +8.87%
    US
    ACRV
    -9.33%

    XOMA Royalty Corporation Completes Acquisition of Turnstone Biologics Corp

    XOMA Royalty Corporation has completed its acquisition of Turnstone Biologics Corp. on August 11, 2025. The acquisition involved a successful tender offer where XOMA purchased all outstanding shares of Turnstone’s common stock for $0.34 per share in cash, along with a contingent value right (CVR) for potential future payments. Following the transaction, Turnstone is now a wholly owned subsidiary of XOMA and will continue its operations under the new ownership.

    Reuters·
    US
    XOMA
    -0.23%
    US
    TSBX
    0.00%
    Reuters·
    US
    XOMA
    -0.23%
    US
    TSBX
    0.00%

    Turnstone Biologics Updates Corporate Governance Structure

    Turnstone Biologics Corp. (TSBX) has announced updates to its corporate governance structure following a merger agreement, which included amendments to its certificate of incorporation and bylaws. The latest analyst rating for TSBX is a Hold with a $1.00 price target. However, Spark's AI Analyst indicates TSBX is underperforming due to financial challenges, declining revenues, and halted clinical studies. The company's current market cap is $8.21M, and it faces uncertainty in its strategic alternatives.

    Tip Ranks·
    US
    TSBX
    0.00%
    Tip Ranks·
    US
    TSBX
    0.00%
    © 2026 Longbridge｜Disclaimer